Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Open accessAbstract
Abstract This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid‐β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost‐effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.
“However, clinical use of AD CSF and PET biomarkers are not currently indicated in most symptomatic individuals to include or exclude AD pathology.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [11]
AD CSF and PET biomarkers are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.
“These tests are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.10,11”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Diagnostic and Statistical Manual of Mental Disorders(DSM)
Leong, F. T. L. (2008) · Sage eBooks · doi:10.4135/9781412963978.n182 · Cited by 10,858 · see citing works
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works
Self-citationBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Self-citationConsensus development methods, and their use in clinical guideline development.
Murphy, M., Black, Lamping, McKee, M., Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,042 · see citing works
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782 · see citing works
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · see citing works
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490 · see citing works
Distinguishing Alzheimer’s disease from other major forms of dementia
Karantzoulis, S., & Galvin, J. E. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.155 · Cited by 385 · see citing works
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H. I., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorová, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 310 · see citing works
Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110458 · Cited by 282 · see citing works
Leone, M. A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., & Bassetti, C. L. (2013) · European Journal of Neurology · doi:10.1111/ene.12043 · Cited by 277 · see citing works
Brożek, J. L., Akl, E. A., Jaeschke, R., Lang, D. M., Bossuyt, P., Glasziou, P., Helfand, M., Ueffing, E., Alonso‐Coello, P., Meerpohl, J., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02083.x · Cited by 270 · see citing works
Duits, F. H., Martínez‐Lage, P., Paquet, C., Engelborghs, S., Lleó, A., Hausner, L., Molinuevo, J. L., Stomrud, E., Farotti, L., Ramakers, I. H. G. B., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.003 · Cited by 260 · see citing works
Self-citationMolinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 198 · see citing works
Self-citationTau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 164 · see citing works
Self-citationFerreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 144 · see citing works
van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 143 · see citing works
Self-citationMitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 123 · see citing works
Jack, C. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1362-3 · Cited by 88 · see citing works
Health economic evaluation of treatments for Alzheimer′s disease: impact of new diagnostic criteria
Wimo, A. B., Ballard, C. G., Brayne, C., Gauthier, S. G., Handels, R. L. H., Jones, R. W., Jönsson, L., Khachaturian, A. S., & Kramberger, M. G. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12167 · Cited by 81 · see citing works
Self-citationCost-Effectiveness of PET in the Diagnosis of Alzheimer Disease
McMahon, P. M., Araki, S. S., Sandberg, E. A., Neumann, P. J., & Gazelle, G. S. (2003) · Radiology · doi:10.1148/radiol.2282020915 · Cited by 81 · see citing works
Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease
Formichi, P., Battisti, C., Radi, E., & Federico, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20602 · Cited by 74 · see citing works
Mo, J.-A., Lim, J., Sul, A.-R., Lee, M. Y., Youn, Y. C., & Kim, H.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116802 · Cited by 66 · see citing works
Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease
Valcárcel‐Nazco, C., Perestelo‐Pérez, L., Molinuevo, J. L., Mar, J., Castilla‐Rodríguez, I., & Serrano-Aguilar, P. G. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132216 · Cited by 53 · see citing works
Self-citationDiagnosing Alzheimer's disease: A systematic review of economic evaluations
Handels, R. L. H., Wolfs, C. A. G., Aalten, P., Joore, M. A., Verhey, F. R. J., & Severens, J. L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.005 · Cited by 48 · see citing works
Self-citationSensitivity and Specificity of Diagnostic Accuracy in Alzheimer’s Disease
Gaugler, J. E., Kane, R. L., Johnston, J. A., & Sarsour, K. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488910 · Cited by 45 · see citing works
Silverman, D. H. S., Cummings, J. L., Small, G. W., Gambhir, S. S., Chen, W., Czernin, J. G., & Phelps, M. E. (2002) · Molecular Imaging and Biology · doi:10.1016/s1536-1632(02)00016-1 · Cited by 43 · see citing works
Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry
Wimo, A., Religa, D., Spångberg, K., et al. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3925 · Cited by 36 · see citing works
Moulin-Romsee, G., Maes, A., Silverman, D. H. S., Mortelmans, L., & Laere, K. V. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00940.x · Cited by 34 · see citing works
The cost of diagnosing dementia in a community setting
Jedenius, E., Wimo, A., Strömqvist, J., et al. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2365 · Cited by 22 · see citing works
Rosén, C., Farahmand, B. Y., Skillbäck, T. B., Nägga, K., Mattsson, N., Kilander, L., Religa, D., Wimo, A. B., Blennow, K., Winblad, B. G., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.04.007 · Cited by 20 · see citing works
Self-citationDiagnostic Utility of CSF Tau and Aβ42 in Dementia: A Meta‐Analysis
Agarwal, R., & Tripathi, C. B. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/503293 · Cited by 16 · see citing works
da Rosa, M. I., Perucchi, J. L., Medeiros, L. R., Fernandes, B. B., dos Reis, M. E. F., & Silva, B. R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132264 · Cited by 11 · see citing works
Liu, B., Tang, Y., Shen, Y., Cen, L., & Min, H. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513507374 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for the clinical application of CSF biomarkers for Alzheimer's disease in the diagnostic evaluation of patients with mild cognitive impairment. Alzheimers Dement 2016. In press.
Cited by
Sorted by citations
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623 · see citing works
“These tests are reserved for atypical, rapidly progressive, or early-onset syndromes, or when comprehensive evaluation is inconclusive.(10,11) In relatively typical cases, an individualized approach to history, examination, and selected laboratory”
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266 · see citing works
Self-citationRecommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
Ismail, Z., Black, S. E., Camicioli, R., Chertkow, H., Herrmann, N., Laforce, R., Montero‐Odasso, M., Rockwood, K., Rosa‐Neto, P., Seitz, D., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12105 · Cited by 245 · see citing works
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183 · see citing works
Anti-amyloid antibody therapies in Alzheimer's disease
Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L. (2023) · Brain · doi:10.1093/brain/awad005 · Cited by 182 · see citing works
Townley, R. A., Graff-Radford, J., Mantyh, W. G., Botha, H., Polsinelli, A. J., Przybelski, S. A., Machulda, M. M., Makhlouf, A. T., Senjem, M. L., Murray, M. E., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa068 · Cited by 145 · see citing works
Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141 · see citing works
Self-citationPreanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99 · see citing works
Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M. J. T., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-018-0273-5 · Cited by 65 · see citing works
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
Brosseron, F., Kolbe, C., Santarelli, F., Carvalho, S., Antonell, A., Castro‐Gomez, S., Tacik, P., Namasivayam, A. A., Mangone, G., Schneider, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.018 · Cited by 47 · see citing works
Self-citationTesting the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40 · see citing works
Niemantsverdriet, E., Feyen, B. F. E., Le Bastard, N., Martin, J.-J., Goeman, J., De Deyn, P. P., Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170927 · Cited by 19 · see citing works
Self-citationKim, E., Di Censo, D., Baraldo, M., Simmons, C., Rosa, I., Randall, K., Ballard, C., Dickie, B. R., Williams, S. C. R., Killick, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91899-5 · Cited by 15 · see citing works
- Authors
- Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., Handels, R., Kramberger, M. G., Kulczyńska, A., Molinuevo, J. L., Mroczko, B., Nordberg, A., Oliveira, C. R., Otto, M., Rinne, J. O., Rot, U., Saka, E., Soininen, H., Struyfs, H., Suardi, S., Visser, P. J., Winblad, B., Zetterberg, H., & Waldemar, G.
- Affiliations
- University of Copenhagen (DK)
- University of Eastern Finland (FI)
- Karolinska University Hospital (SE)
- Neurochemistry Laboratory, Faculty of Medicine, CHUC—Coimbra University Hospital, CNC, CNC.IBILI—Center for Neuroscience and Cell Biology University of Coimbra Coimbra Portugal
- University of Antwerp (BE)
- University of Gothenburg (SE)
- University of Geneva (CH)
- Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Maastricht University (NL)
- Ljubljana University Medical Centre (SI)
- Department of Neurodegeneration Diagnostics Medical University of Białystok Białystok Poland
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic i Universitari IDIBAPS Barcelona Spain
- Medical University of Białystok (PL)
- Karolinska Institutet (SE)
- Unidade Local de Saúde de Coimbra (PT)
- Universität Ulm (DE)
- University of Turku (FI)
- Hacettepe University Hospital (TR)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Waldemar, Gunhild
- ORCID
- Simonsen, Anja Hviid
- Herukka, Sanna-Kaisa
- Bjerke, Maria
- Blennow, Kaj
- Engelborghs, Sebastiaan
- Frisoni, Giovanni B.
- Galluzzi, Samantha
- Handels, Ron
- Kramberger, Milica G.
- Mroczko, Barbara
- Nordberg, Agneta
- Oliveira, Catarina Resende
- Otto, Markus
- Rinne, Juha O.
- Rot, Uroš
- Saka, Esen
- Soininen, Hilkka
- Visser, Pieter Jelle
- Winblad, Bengt
- Zetterberg, Henrik
- Waldemar, Gunhild
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-10-27
- Volume
- 13
- Issue
- 3
- Pages
- 274-284
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2543998349
- Cited by
- 138
- References
- 39
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 8 · 2022: 13 · 2021: 20 · 2020: 12 · 2019: 30 · 2018: 20 · 2017: 8 · 2016: 1
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- UEF eRepo (University of Eastern Finland) (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by-nc-nd)
- UCL Discovery (University College London) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Innovationsfonden (0603‐00470B; AHS, GW)
- Academy of Finland (263193; SKH, HS)
- Ministero della Salute
- EU Joint Programme – Neurodegenerative Disease Research (N 469/2012 (GBF, SG, SS))
- ZonMw (629000002 (RH, PJV))
- Fundação para a Ciência e a Tecnologia (JPND/0005/2011; CRO, IB)
- Javna Agencija za Raziskovalno Dejavnost RS (A3‐0001; MGK, UR)
- Instituto de Salud Carlos III (PI11/03023; JLM)
- German Network for Motor Neuron Diseases (01GM1103A)
- Fonds Wetenschappelijk Onderzoek
- General Electric
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebrospinal fluid biomarkers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Humans, Peptide Fragments, Biomarkers, Databases, Bibliographic, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
